Modification of ventriculo–arterial coupling by spironolactone in nonischemic dilated cardiomyopathy

Mark A. Lawson, David E. Hansen, Deepak K. Gupta, Susan P. Bell, Douglas W. Adkisson, Ravinder R. Mallugari, Douglas B. Sawyer, Henry Ooi and Marvin W. Kronenberg*

VA Tennessee Valley Health Care System, Vanderbilt University Medical Center, Nashville, TN 37222, USA

Abstract

Aims We sought to clarify the role of ventriculo–arterial (V–A) coupling in the treatment of nonischemic dilated cardiomyopathy (NIDCM) by adding a mineralocorticoid receptor antagonist (MRA) to conventional anti-failure therapy.

Methods and results We employed cardiac magnetic resonance imaging to quantify left ventricular (LV) contractility and V–A coupling in normal subjects at rest \((n = 11)\) and in patients with NIDCM \((n = 12)\) before and after long term anti-failure therapy, in which MRA was added to conventional anti-failure therapy. After \(\geq 6\) months’ treatment in NIDCM patients, LV volumes and mass decreased, and the LV ejection fraction increased from a median of 24% \((17, 27)\) (interquartile range IQR) to 47 \((42, 52)\) \(P < 0.002\), with a marked reduction in arterial elastance \((Ea)\) from 2.89 mmHg/mL \((2.34, 4.0)\) to 1.50 \((1.29, 1.95)\) \(P < 0.002\), similar to Ea of normal subjects, 1.53 \((1.34, 1.67)\) \(P > 0.05\). The V–A coupling ratio, \(Ea/\)end-systolic elastance (single-beat method), decreased by \(-1.08 \(-1.96, -0.55\), \(P = 0.003\), as did \(Ea/end-systolic pressure/end-systolic pressure ratio\), \(-0.54 \(0.35, 0.87\), \(P = 0.002\). The preload recruitable stroke work (PRSW) increased as did PRSW indexed for \(Ea\) (both \(P = 0.002\), which reflected ‘total circulatory performance’.

Conclusions In NIDCM, adding MRA to conventional anti-failure therapy markedly improved LV ejection fraction and reduced peripheral vascular resistance, due to both improved LV contractility and especially to enhanced V–A coupling, as \(Ea\) decreased to normal. Total circulatory performance was a sensitive indicator of both LV pump performance and the arterial loading conditions.

Keywords Nonischemic cardiomyopathy; Ventricular/vascular coupling haemodynamics; Magnetic resonance imaging; Spironolactone

Introduction

Nonischemic dilated cardiomyopathy (NIDCM) is characterized by depressed left ventricular (LV) contractility with adverse LV remodelling, myocardial fibrosis and heart failure (HF) with reduced ejection fraction (HFrEF).1 This constellation activates compensatory neurohumoral mechanisms that increase systemic vascular resistance (SVR).2

Standard therapy for HFrEF affects both the LV myocardium and the peripheral circulation. Beta-adrenergic blocking drugs (BBs), such as carvedilol, improve myocardial structure and function3 and reduce SVR.4 Angiotensin-converting enzyme inhibitors (ACE-I) reduce perivascular collagen5 and reduce SVR,5 reducing unfavourable LV remodelling.6 Randomized clinical trials in HFrEF patients reduced mortality by treatment with mineralocorticoid receptor antagonist(s) (MRA).7 Aldosterone causes excess vascular stiffness8 and stimulates LV interstitial fibrosis,9 which can be blocked and partly reversed by MRA.10,11 Relatively little attention has been paid to the role of the peripheral vasculature in improving LV performance in HFrEF.12,13 However, MRA up-regulate endothelial nitric oxide,14 causing peripheral vascular dilatation and lower SVR,15 which may contribute to beneficial LV remodelling.16,17

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
The coupling of LV contractile properties with the peripheral circulation [ventriculo-arterial (V–A) coupling] can be expressed in the pressure–volume plane as the interaction of the LV end-systolic pressure (ESP) volume relationship (ESPV) and the systemic arterial elastance (Ea).\textsuperscript{18} Other methods for estimating LV performance include the ratio of LV end-systolic pressure/end-systolic volume,\textsuperscript{19} the single-beat calculation of LV elastance,\textsuperscript{20} preload recruitable stroke work (PRSW),\textsuperscript{21} and its single-beat calculation.\textsuperscript{22}

We sought to clarify the influence of V–A coupling on changes in LV ejection fraction (LVEF) and indices of LV contractility during the treatment of NIDCM. For this, we used serial cardiac magnetic resonance imaging (CMR) and the above-mentioned methods in patients with NIDCM before and after adding MRA to conventional anti-failure therapy above-mentioned methods in patients with NIDCM before and after adding MRA to conventional anti-failure therapy. For this, we used serial cardiac magnetic resonance imaging (CMR) and the above-mentioned methods in patients with NIDCM before and after adding MRA to conventional anti-failure therapy. We enrolled patients with newly diagnosed NIDCM who were uncontrolled atrial fibrillation, current spironolactone therapy, no history of hypertension, diabetes mellitus, or heart disease. They were studied at rest at a single time point using similar CMR technique.

This investigation conforms with the principles outlined in the Declaration of Helsinki. The NIDCM study was approved by both the Vanderbilt and Nashville Veterans Affairs Institutional Review Boards. The normal subject study was approved by the Vanderbilt Institutional Review Board. All patients provided written informed consent.

Cardiac magnetic resonance imaging acquisition and analysis

Cardiac magnetic resonance imaging was performed using a commercially available 1.5-T Siemens Magnetom Avanto scanner (Erlangen, Germany) using methods previously published.\textsuperscript{23} During CMR, the blood pressure was measured using an magnetic resonance imaging compatible automated cuff sphygmanometer, and heart rate was recorded from telemetry.

Data analysis

Cardiac magnetic resonance imaging

The end-diastolic and end-systolic endocardial borders on CMR were outlined using system software (Argus software Version B17, Siemens, Erlangen, Germany) (NIDCM patients) or Medis software (normal subjects) and adjusted manually as needed to calculate LVEF. The end-diastolic volume (EDV), end-systolic volume (ESV) and stroke volume (SV), were divided by body surface area, yielding these indices (mL/m$^2$). Simplified pressure–volume diagrams were constructed from CMR data and the noninvasive blood pressure values for each patient.

Echocardiography acquisition and analysis

All subjects underwent standard two-dimensional, M-mode, and Doppler transthoracic echocardiography according to American Society of Echocardiography guidelines. Imaging was performed using Phillips IE33 echocardiographs using standard transducers. For calculation of $E_{\text{ndest}}$, the ratio of the pre-ejection period (PEP) to the total systolic period (Q-S2 interval) was determined using Doppler tracings of the LV outflow tract. Among normal subjects, SV was calculated using the LV outflow tract diameter and velocity time integral.\textsuperscript{27}

Methods

Study design

We enrolled patients with newly diagnosed NIDCM who were recruited from the Vanderbilt University Medical Center and the Veterans Affairs Tennessee Valley Medical Center. Eligible participants were 18–80 years old, of any ethnic background and either sex, New York Heart Association Functional Class II–IV, with an echocardiographic LVEF of $\leq$35% and serum potassium level less than 5.0 mmol/L (5 mEq/dL) while on medical therapy for HF (including stable BB and ACE-I/ARB for $\geq$3 months). Exclusion criteria were the need for an implantable cardioverter-defibrillator, evidence of prior myocardial infarction on electrocardiogram, a positive stress test or coronary artery disease with $\geq$50% stenosis in a major epicardial artery at angiography, severe chronic obstructive airway disease precluding adenosine use, creatinine $\geq$3 mmol/L (3 m$\mu$mol/L), glomerular filtration rate <30 mL/min/1.73m$^2$, uncontrolled atrial fibrillation, current spironolactone therapy, and physician preference. Of 590 screened clinic visits, 16 patients who met the inclusion and exclusion criteria were recruited. Among these, four did not complete the study due to an erroneous inclusion of one patient, bronchoconstriction from adenosine use for CMR ($n=1$), implantation of implantable cardioverter-defibrillator ($n=1$), and patient withdrawal ($n=1$), leaving a total of 12 patients who completed the study protocol. Significant coronary atherosclerosis was excluded by coronary angiography ($n=10$) or the absence of ischemia or infarction on nuclear stress perfusion imaging ($n=2$).

The NIDCM patients underwent a 5 day trial of spironolactone to assess tolerability. After this drug was discontinued, the patients underwent CMR at baseline and after $\geq$6 months of spironolactone therapy added to ACE-I/ARB and BB anti-failure treatment. The CMR protocol is described later. The patients took spironolactone 25 mg daily for $\geq$6 months, up-titrated to 50 mg daily if possible. The doses of ACE-I/ARB and BB drugs remained constant. Eleven normal subjects were recruited by advertisement and had no history of hypertension, diabetes mellitus, or heart disease. They were studied at rest at a single time point using similar CMR technique.

We sought to clarify the in https://doi.org/10.1002/ehf2.13161
**Indices of contractility**

**End-systolic pressure** The ESP (Pes) was calculated as 0.9 × systolic blood pressure (SBP).\(^{28}\)

**End-systolic elastance (single-beat method)** A single-point estimate of the LV contractile state was calculated as

\[ E_{es (sb)} = \frac{(P_d - (E_{Nd (est)} \times P_s \times 0.9))}{SV \times E_{Nd (est)}}, \]

in which \( E_{es (sb)} \) = end-systolic elastance using a single-beat method (SBM) (mmHg/mL), \( P_d \) = systemic arterial diastolic pressure (mmHg), \( P_s \) = systolic arterial pressure (mmHg), \( SV \) = stroke volume (mL), and \( E_{Nd (est)} \) = group averaged LV elastance at the onset of ejection. To calculate \( E_{Nd (est)} \), the ratio of the PEP to the total systolic period (Q-S₂) interval was determined using Doppler tracings of the LV outflow tract on echocardiograms obtained as baseline or follow-up studies. These data were available in 10 of 12 HF patients at baseline and for five patients who had echocardiograms within 1.5 years after completing the study. The mean values for PEP and Q-S₂ were applied to the remaining HF patients. All normal subjects had echocardiograms within 6 hours of their CMR study.

Magnetic resonance imaging was employed to calculate SV instead of echocardiography as performed previously.\(^{26}\) To evaluate our CMR adaptation, in 10 normal subjects, echocardiography was employed for estimating PEP, Q-S₂, and SV, and results were compared with end-systolic elastance (single-beat method) [Ees (sb)] using CMR SV.

**End-systolic pressure/end-systolic volume ratio** The ESP/end-systolic volume (P/V) ratio was calculated as Pes/Ves.\(^{4}\)

**End-systolic volume pressure of 100 mmHg** The ESV at a pressure of 100 mmHg (End-systolic volume at pressure 100 mmHg) was calculated as an expression of contractility, needing minimal extrapolation, if any, from measured values, similar to the work of others.\(^{29}\)

**Preload recruitable stroke work** This was expressed as \( M_w = SW/EDV - Vw \), where \( Vw \) is the X-axis intercept of this slope and \( M_w \) is the slope of the relation,\(^{21}\) employing a single-beat method (SBM), \( SBM_w. \)

**Systemic arterial properties**

**Total systemic vascular resistance** This was calculated as total systemic vascular resistance (TVR) = 80 × MAP/CO (dyne s cm \(^{-5}\)), where \( CO \) = cardiac output (L/min), converted to Wood units (mmHg-min/L).

**Arterial elastance** The Ea was expressed as Pes/SV.\(^{18}\)

**Ventriculo-arterial coupling**

**Arterial elastance/end-systolic elastance (single-beat method)** The V-A coupling ratio expressed as the relation of Ea and LV contractility expressed as Ees (sb),\(^{18}\) Ea/Ees(sb).

**Arterial elastance/end-systolic pressure/end-systolic volume ratio** The V-A coupling ratio expressed as the relation of Ea and LV contractility using the end-systolic Pes/Ves ratio\(^{6}\) Ea/[P/V].

**Total circulatory performance** To evaluate the hypothesis that Ea is incorporated in PRSW,\(^{30,31}\) we compared its main component, SW/EDV, with \( SBM_w \) and then indexed the result for Ea by comparing the relation of \([SW/EDV]/Ea\) to \( SBM_w \). Incorporating Ea was considered an index of total circulatory performance (TCP) that reflected both LV contractility and arterial loading conditions.

**Statistical analysis**

Descriptive statistics are presented as median (25th to 75th percentile) or counts (percentages). Either the Wilcoxon rank-sum or Fisher’s exact test was used for comparisons between normal subjects and patients with NIDCM. For paired data examining changes in parameters of cardiac structure and function before and after spironolactone, the Wilcoxon signed-rank test was used. Comparisons of the slopes of the relationships between SW/EDV (or \([SW/EDV]/Ea\)) and \( SBM_w \) before and after MRA therapy were performed using linear regression with an interaction term with robust adjustment. Differences between the slopes of SW/EDV to \( SBM_w \) and [SW/EDV]/Ea to \( SBM_w \) were assessed using the ‘suest’ package in Stata. Analyses were performed using Stata v15.0 (Stata Corp., Austin, TX, USA).

**Results**

**Baseline characteristics**

Selected baseline data of each patient group are listed in Tables 1 and 2. Other details of the NIDCM patients were published previously.\(^{23}\) The NIDCM and normal subjects were of similar ages. Before study entry, the median duration of taking a BB and either an ACE-I or ARB drug was 21 weeks, and the median duration on stable doses of BB was 16 weeks. The baseline CMR study was at a median 6 weeks (IQR 4–0006).

**Indices of contractility**

**End-systolic pressure** The ESP (Pes) was calculated as 0.9 × systolic blood pressure (SBP).\(^{28}\)

**End-systolic elastance (single-beat method)** A single-point estimate of the LV contractile state was calculated as

\[ E_{es (sb)} = \frac{(P_d - (E_{Nd (est)} \times P_s \times 0.9))}{SV \times E_{Nd (est)}}, \]

in which \( E_{es (sb)} \) = end-systolic elastance using a single-beat method (SBM) (mmHg/mL), \( P_d \) = systemic arterial diastolic pressure (mmHg), \( P_s \) = systolic arterial pressure (mmHg), \( SV \) = stroke volume (mL), and \( E_{Nd (est)} \) = group averaged LV elastance at the onset of ejection. To calculate \( E_{Nd (est)} \), the ratio of the PEP to the total systolic period (Q-S₂) interval was determined using Doppler tracings of the LV outflow tract on echocardiograms obtained as baseline or follow-up studies. These data were available in 10 of 12 HF patients at baseline and for five patients who had echocardiograms within 1.5 years after completing the study. The mean values for PEP and Q-S₂ were applied to the remaining HF patients. All normal subjects had echocardiograms within 6 hours of their CMR study.

Magnetic resonance imaging was employed to calculate SV instead of echocardiography as performed previously.\(^{26}\) To evaluate our CMR adaptation, in 10 normal subjects, echocardiography was employed for estimating PEP, Q-S₂, and SV, and results were compared with end-systolic elastance (single-beat method) [Ees (sb)] using CMR SV.

**End-systolic pressure/end-systolic volume ratio** The ESP/end-systolic volume (P/V) ratio was calculated as Pes/Ves.\(^{4}\)

**End-systolic volume pressure of 100 mmHg** The ESV at a pressure of 100 mmHg (End-systolic volume at pressure 100 mmHg) was calculated as an expression of contractility, needing minimal extrapolation, if any, from measured values, similar to the work of others.\(^{29}\)

**Preload recruitable stroke work** This was expressed as \( M_w = SW/EDV - Vw \), where \( Vw \) is the X-axis intercept of this slope and \( M_w \) is the slope of the relation,\(^{21}\) employing a single-beat method (SBM), \( SBM_w. \)

**Systemic arterial properties**

**Total systemic vascular resistance** This was calculated as total systemic vascular resistance (TVR) = 80 × MAP/CO (dyne s cm \(^{-5}\)), where \( CO \) = cardiac output (L/min), converted to Wood units (mmHg-min/L).

**Arterial elastance** The Ea was expressed as Pes/SV.\(^{18}\)
Table 1  Characteristics at time of baseline CMR

|                      | NIDCM N = 12 | Normal N = 11 | P    |
|----------------------|--------------|---------------|------|
| Age (years)          | 52 (45, 55)  | 55 (52, 58)   | 0.039|
| Male                 | 8 (67%)      | 3 (27%)       | 0.10 |
| Medications          |              |               |      |
| Beta blocker         | 12 (100%)    | 0 (0%)        |      |
| ACE-I or ARB         | 12 (100%)    | 0 (0%)        |      |
| Diuretic             | 7 (58%)      | 0 (0%)        |      |
| BMI (kg/m²)          | 30.0 (25.7, 34.3) | 24.7 (21.0, 27.8) | 0.023|
| LVEDVI (mL/m²)       | 82 (74, 91)  | 63 (55, 75)   |      |
| LVEF (%)             | 24 (17, 27)  | 66 (55, 75)   |      |
| NYHA class           |              |               |      |
| 1                    | 0 (0%)       | 7 (100%)      |      |
| 2                    | 5 (42%)      | 0 (0%)        |      |
| 3                    | 7 (58%)      | 0 (0%)        |      |
| Heart rate (bpm)     | 67 (58, 71)  | 62 (57, 68)   | 0.48 |
| Systolic BP (mmHg)   | 121 (115, 125)| 120 (113, 125)| 0.62 |
| Diastolic BP (mmHg)  | 67 (63, 73)  | 72 (67, 82)   | 0.25 |
| MAP (mmHg)           | 84 (80, 90)  | 87 (82, 95)   | 0.39 |

Median (interquartile range). Pairwise comparisons between groups using Wilcoxon rank sum test, with Bonferroni corrected threshold P < 0.0166 for significance. Ea, arterial elastance (mmHg/mL); Ea/[Pes/Ves], arterial elastance/end-systolic pressure/end-systolic volume ratio; Ees (sb), end-systolic elastance (single-beat method) (mmHg/mL); ESV-100, end-systolic volume at 100 mmHg (mL); LV, left ventricular; LVEDVI, LV end-diastolic volume index; LVEF, LV ejection fraction; NIDCM, nonischemic dilated cardiomyopathy; NYHA, New York Heart Association.

Table 2  Baseline parameters of LV performance and ventriculo–arterial coupling

|                      | NIDCM N = 12 | Normal N = 11 | P    |
|----------------------|--------------|---------------|------|
| LVEF (%)             |              |               |      |
| LVEDVI (mL/m²)       | 24 (17, 27)  | 66 (62, 67)   | <0.001|
| LVESVI (mL/m²)       | 63 (56, 78)  | 19 (17, 28)   | <0.001|
| LSVI (mL/m²)         | 19 (14, 21)  | 41 (37, 47)   | <0.001|
| LV mass (g)          | 169 (154, 203)| 69 (49, 77)   | <0.001|
| TVR (Wood units)     | 2.69 (2.23, 3.85)| 1.48 (1.38, 1.75)| <0.001|
| Ea                   | 2.89 (2.34, 4.00)| 1.53 (1.34, 1.67)| <0.001|
| Ea/ESV              | 0.96 (0.75, 1.43)| 1.44 (1.26, 1.64)| 0.016 |
| Ea/Ees (sb)          | 3.08 (2.54, 3.78)| 0.95 (0.91, 1.11)| <0.001|
| Pes/Ves             | 0.83 (0.65, 0.95)| 3.04 (2.63, 3.49)| <0.001|
| Vw                   | 16 (–14, 38)  | –38 (–39, –24) | 0.001 |
| ESV-100             | 121 (104, 148)| 30 (27, 37)   | <0.001|
| SBMw                 | 35 (24, 45)  | 113 (101, 119)| <0.001|
| TCP                 | 7.4 (3.4, 11.4)| 40.2 (35.2, 43.8)| <0.001|
| Ea/Pes/Ves              | 3.24 (2.65, 4.83)| 0.51 (0.49, 0.69)| <0.001|
| Vw                   | 71.3 (60.2, 90.2)| 51.1 (49.2, 56.4)| 0.012 |

Median (interquartile range). Paired comparisons between groups using Wilcoxon rank sum test, with Bonferroni corrected threshold P < 0.0166 for significance. Ea, arterial elastance (mmHg/mL); Ea/[Pes/Ves], arterial elastance/end-systolic pressure/end-systolic volume ratio; Ees (sb), end-systolic elastance (single-beat method) (mmHg/mL); ESV-100, end-systolic volume at 100 mmHg (mL); LV, left ventricular; LVEDVI, LV end-diastolic volume index; LVEF, LV ejection fraction; LVEF, LV end-diastolic volume index; LSVI, LV stroke volume index; Pes/Ves, end-systolic pressure/end-systolic volume ratio; SBMw, slope of preload recruitable stroke work relation (single-beat method) (erg.cm⁻³ 10⁻⁴); TCP, total circulatory performance (stroke work/end-diastolic volume/Ea); TVR, total vascular resistance; Vw, end-systolic volume at SBP 0 mmHg (mL); Vw, LV volume at Stroke Work 0.

Left ventricular remodelling in nonischemic dilated cardiomyopathy

Following ≥6 months of spironolactone therapy (median 45 weeks, IQR 27–74) CMR showed evidence for beneficial remodelling, with significant reductions in LV EDVI and ESVI, associated with an increase in SVI and LVEF (Figure 1, Table 3).

Indices of contractility

There were significant changes in the P/V ratio, ESV-100, SW/EDV, and SBMw, all consistent with improved contractility, except for Ees (sb) (Figure 2, Table 3). At baseline, Ees (sb) was 0.96 (0.75, 1.43) mmHg/mL, which was less than in our normal subjects and normal values in the literature, and was 0.79 (0.69, 1.11) at follow-up (P = 0.12). With a decrease in ESV, the calculated V0 shifted leftward.

Peripheral circulation

There was a strong correlation between Ea and TVR in NIDCM patients (R² = 0.85, P < 0.0001). The Ea of NIDCM patients was 2.89 (2.34, 4.00) mmHg/mL at baseline, and as SV increased, Ea declined sharply to 1.50 (1.29, 1.95) at follow-up (P = 0.002).
Figure 1  Pressure–volume relations of patients with nonischemic dilated cardiomyopathy before (red) and after anti-failure therapy (blue). Dashed lines show Ees (sb) and calculated Vo. ESV-100, end-systolic volume pressure of 100 mmHg; LVEF, left ventricular ejection fraction; P/V, end-systolic pressure/end-systolic volume; SBM, single-beat method.

Table 3  LV performance and ventriculo–arterial coupling at baseline and after adding mineralocorticoid receptor antagonist in NIDCM patients

|                      | Baseline          | Follow-up         | Change             | P     |
|----------------------|-------------------|-------------------|--------------------|-------|
| Heart rate (bpm)     | 67 (58, 71)       | 72 (65, 76)       | 5 (3, 12)          | 0.021 |
| Systolic BP (mmHg)   | 121 (115, 125)    | 122 (112, 134)    | 2 (–5, 11)         | 0.46  |
| Diastolic BP (mmHg)  | 67 (63, 73)       | 72 (65, 79)       | 4 (–1, 10)         | 0.059 |
| MAP (mmHg)           | 84 (80, 90)       | 89 (81, 97)       | 1 (–1, 10)         | 0.21  |
| LVEF (%)             | 24 (17, 27)       | 47 (42, 52)       | 22 (15, 34)        | 0.002 |
| LVEDVI (mL/m²)       | 82 (74, 91)       | 74 (59, 82)       | –8 (–14, –5)       | 0.003 |
| LVESVI (mL/m²)       | 63 (56, 78)       | 36 (31, 46)       | –24 (–32, –19)     | 0.002 |
| LVSVI (mL/m²)        | 19 (14, 21)       | 36 (28, 40)       | 15 (9, 19)         | 0.002 |
| LV mass (g)          | 169 (154, 203)    | 151 (138, 190)    | –12 (–21, –6)      | 0.008 |
| TVR (Wood units)     | 2.69 (2.23, 3.85) | 3.4 (1.15, 1.87)  | –1.17 (–2.06, –0.73) | 0.002 |
| Ea                   | 2.89 (2.34, 4.00) | 1.50 (1.29, 1.95) | –1.19 (–2.26, 0.53) | 0.002 |
| Ees (sb)             | 0.96 (0.75, 1.43) | 0.79 (0.69, 1.11) | –0.10 (–0.35, 0.02) | 0.12  |
| Vo ml                | 16 (–14, 38)      | –56 (–73, –37)    | –37 (–102, –34)    | 0.003 |
| Vw                   | 71.3 (60.2, 90.2) | 61.7 (47.0, 79.0) | –11.9 (–18.1, –4.4) | 0.004 |
| ESV-100              | 121 (104, 148)    | 60 (52, 82)       | –54 (–63, –39)     | 0.002 |
| Ea/Ees (sb)          | 3.08 (2.55, 3.78) | 1.89 (1.75, 2.07) | –1.08 (–1.96, –0.55) | 0.003 |
| Pes/Ves              | 0.83 (0.65, 0.95) | 1.52 (1.17, 1.70) | 0.70 (0.35, 0.79)  | 0.002 |
| SBMₚw                | 35.1 (24.0, 44.7) | 74.1 (61.5, 77.5) | 31.0 (25.8, 54.2)  | 0.002 |
| TCP                  | 7.4 (3.4, 11.4)   | 25.0 (22.7, 33.9) | 19.3 (13.0, 28.9)  | 0.002 |
| Ea/Pes/Ves           | 3.24 (2.65, 4.83) | 1.12 (0.91, 1.4)  | 0.54 (0.35, 0.87)  | 0.002 |

Median (interquartile range). Ea, arterial elastance (mmHg/mL); Ea/Pes/Ves, arterial elastance/end-systolic pressure/end-systolic volume ratio; Ees (sb), end-systolic elastance (single-beat method) (mmHg/mL); ESV-100, end-systolic volume at 100 mmHg (mL); LV, left ventricular; LVEDVI, LV end-diastolic volume index; LVEF, LV ejection fraction; LVESVI, LV end-systolic volume index; LVSVI, LV stroke volume index; Pes/Ves, end-systolic pressure/end-systolic volume ratio; SBMₚw, slope of preload recruitable stroke work relation (single-beat method) (erg cm⁻³ 10³); TCP, total circulatory performance (stroke work/end-diastolic volume/Ea); TVR, total vascular resistance; Vo, end-systolic volume at SBP 0 mmHg (mL); Vw, LV volume at Stroke Work 0.
Ventriculo–arterial coupling

Arterial elastance/end-systolic elastance (single-beat method)
At baseline, patients with NIDCM, compared with normal subjects, had a greater V–A coupling ratio, Ea/Ees (sb), due to greater Ea and lower Ees (sb). At follow-up, Ea declined sharply to a value similar to normal subjects (P > 0.05) (Tables 2 and 3) because of the increase in SV. However, the V–A coupling ratio, Ea/Ees (sb), was still greater than in normal subjects (P < 0.001) (Tables 2 and 3).

Arterial elastance/end-systolic pressure/end-systolic volume ratio
At baseline, patients with NIDCM had a similarly greater V–A coupling ratio compared with normal subjects (Table 2). There was a marked decrease in this value at follow-up (Table 3, Figure 3), although this measure of V–A coupling remained greater than normal (P < 0.001).

Total circulatory performance
At baseline, TCP was markedly different between NIDCM and normal subjects, but lay along the same regression line (Figure 4). At baseline, in the NIDCM patients, the slope of the relation between [SW/EDV] and Mw was similar to the slope of the relation when indexed for Ea (Figure 5, Panel A vs. C) (P = 0.61). After MRA, the values of [SW/EDV] increased

Figure 2 Estimates of left ventricular contractility before and after anti-failure therapy. Please see text for abbreviations.

Figure 3 Changes in ventriculo–arterial coupling using two definitions of left ventricular contractility. (A). Arterial elastance/end-systolic elastance (single-beat method) [Ea/Ees (sb)]. (B). Arterial elastance/end-systolic pressure/end-systolic volume ratio (Ea/[Pes/Ves]). ESV, end-systolic volume; SBM, single-beat method.

Figure 4 Relation between preload recruitable stroke work as SBMw vs. [SW/EDV]/Ea in patients with nonischemic dilated cardiomyopathy and normal subjects. The values are markedly different between the two groups but the relations are similar. Closed circles: nonischemic dilated cardiomyopathy. Open circles: normal. ESV, end-systolic volume; SBM, single-beat method.
markedly, but the slope of the [SW/EDV] relation to M_w remained similar to baseline (Panel A vs. B) (P = 0.254). In contrast, however, after MRA, the slope of the relation of [SW/EDV]/Ea to M_w was significantly greater than without this adjustment (Panel B vs. D) (P = 0.0003) and significantly greater than its baseline value (Panel D vs. C) (P = 0.033).

**Discussion**

Among patients with NIDCM, the addition of MRA to BB and ACE-I/ARB produced beneficial LV remodelling, greater LV contractility, and normalization of Ea, indicating strongly enhanced V–A coupling, all leading to a marked improvement in LVEF.

**Aldosterone and ventriculo–arterial coupling in heart failure**

Randomized clinical trials in HFrEF patients have demonstrated reductions in mortality rates with MRA, likely due to reducing the effects of circulating aldosterone. The serum aldosterone and the aldosterone/renin ratio are significant factors in peripheral vascular stiffness, and spironolactone can improve this by up-regulating arterial nitric oxide synthase and reducing endothelial dysfunction.

The V–A coupling has been studied in untreated patients with NIDCM and normal subjects, with greater Ea/Ees in NIDCM (2.02 vs. 0.46). At baseline, our results were similar. Three prior studies examined V–A coupling after long-term anti-failure therapy including MRA. These found 18–42% decreases in the V–A coupling ratio, but with variability in the estimates of LV contractility. In the present study, we found a sharp decrease in Ea, but no change in Ees (sb), producing an average 32% decrease in Ea/Ees (sb).

**Beneficial left ventricular remodelling compared with peripheral vascular effects**

Anti-failure therapy has direct myocardial effects. BB drugs benefit myocardial metabolism. ACE-I reduce myocardial inflammation, vascular remodelling, and the rate of adverse LV remodelling. Spironolactone inhibits myocardial collagen synthesis.

However, even lacking myocardial effects, drugs such as nitroprusside can reduce SVR, increase SV, and decrease ESV, thus increasing LVEF. Similarly, spironolactone enhances
peripheral vascular dilatation both in animal models and in patients. Thus, LVEF could, in theory, improve by reducing SVR, as seen here, without improving LV contractility. In fact, however, there was both a decrease in SVR and an increase in contractility.

Classic experiments in the isolated supported heart show that ESPVR is affected little by the arterial characteristics but LV performance, as judged by SV and SW, increases with lower SVR, which is also supported by an analytical model. ‘Optimal’ LV performance depends on the clinical context. Thus, greater SV might be the goal in treating HFrEF, rather than SW, although greater SW is associated with greater LV mechanical efficiency.

Parameters of contractility in NIDCM

Several parameters of contractility (P/V, ESV-100, V0, and PRSW), suggested an increase in contractility, except for Ees (sb). All these indices depend on SV, which increased greatly as the SVR decreased. The equation for Ees (sb) (refer to Methods) shows the marked influence of SV on this, because SBP did not change significantly (median difference 1 mmHg) but SVI increased markedly, yielding no increase in Ees (sb). Thus, it is likely that Ees (sb) is inadequate to estimate LV contractility in this situation. Similar to the present study, Maurer et al. analysed the effects of carvedilol on patients with HFrEF and found an increase in Pes/Ves, an increase in SV, and a significant decrease in Ea/Pes/Ves in responders to carvedilol. Dekleva et al. analysed elderly patients in the CIBIS study and found similar results to ours, including no change in Ees (sb), which they termed Elv.

There may be other influences on the Ees (sb) result. Possibly, the myocardial mechanism of ‘shortening deactivation’ is responsible for the Ees (sb) result, based on experiments finding lower ESPVR with reduced afterload and lower ESP as SV increased. Others found lower ESP on ejecting beats than isovolumic beats, and that LV pressure is reduced at greater flow rates, termed ‘flow-induced deactivation’. The Ees (sb) might be affected by these LV mechanical properties or also by reflex feedback. Consistent with our results using Ees (sb), afterload reduction with nitroprusside had no effect on another single-beat estimate of contractility.

Incorporation of peripheral vascular resistance into analysis of left ventricular contractility

Preload recruitable stroke work

The PRSW, expressed as SBMw, increased sharply with MRA, consistent with an increase in LV contractility (Table 3, Figure 4A,B) but with no significant difference in the slopes of the relations between SW/EDV and SBMw after treatment. PRSW is a highly linear index of LV contractility in the intact dog model with autonomic blockade, not affected by phenylephrine or nitroprusside infusions. Its linearity is thought due to incorporating Ea into PRSW, where, mathematically, a linear SW–EDV relation could only exist if there is autoregulation in which Ea changes with ED volume. McClain et al. concluded that PRSW was a descriptor of TCP, rather than only intrinsic myocardial performance. The mechanism of such autoregulation is unclear because beta-adrenergic blockade and atropine were employed in these studies.

Total circulatory performance

In this study, we intentionally incorporated Ea into the analysis of SW/EDV vs. SBMw and there was a much steeper slope of the [SW/EDV]/Ea relation to SBMw following anti-failure therapy (which we termed total circulatory performance, TCP) (Figure 4C vs. Figure 4D). This is likely due to both greater SV and reduced Ea and contrasts with the lack of change in the slope of SBMw (Figure 5A vs. Figure 5B), in spite of the marked decrease in Ea. This direct incorporation of Ea into the [SW/EDV] relation demonstrated both increased contractility and the importance of Ea in TCP. The results of PRSW and TCP in the treatment of actual patients with HFrEF are a step beyond prior analyses in animal models.

Possible effects of fibrosis on left ventricular performance

The large increase in LVEF in our patients with NIDCM was greater than in other studies of HFrEF using MRA. This may be a specific attribute of our study population, compared with chronic NIDCM. Our patients had a relatively short duration of HF symptoms, no replacement fibrosis, and little interstitial fibrosis. Other studies of MRA in HFrEF have not documented the duration of HF symptoms or the amount of interstitial fibrosis.

Limitations

The fewer echocardiograms carried out after the follow-up CMR study were a potential limitation for not having paired PEP and the total duration of systole (QS interval) when calculating Ees (sb) for all patients. However, this was of minimal importance, because the main determinants of Ees (sb) are SBP, SV, and the complex regression equation that specifies End as shown in the formula (Methods). The total duration of systole is similar in normal and HF patients, while PEP is longer and LVET is shorter (the latter consistent with reduced SV in HF). The mean difference between PEP in HF patients and normal subjects is 42 ms, which is 30% greater than normal. We calculated the effect of PEP on Ees (sb), using our results for SBP and SV at follow-up. Even including a very slight increase in PEP, there would still be a significant difference in the slopes of the relations between SW/EDV and SBMw.
significant 10% decrease in PEP, concordant with much improved contractility, would change Ees (sb) by only 0.1 mmHg/mL, a minimal difference. These factors support our Ees (sb) results.

The calculation of Ees (sb) led to a decrease in Vp to negative values in most patients. While this shift is consistent with improved contractility, we did not emphasize this because the LV ESPVR is likely curvilinear at non-physiological low pressures.29

Others have studied V–A coupling in HF by measuring pulsatile arterial loading.47 But nevertheless, even with simpler methods, the present study showed highly significant changes in V–A coupling. We studied a relatively small group of patients, but CMR is very accurate for defining LV volume25 and shows significant changes using fewer subjects.48

Conclusions

Adding MRA to anti-failure therapy with BB and ACE-I/ARB drugs, produced a marked improvement in LVEF due primarily to reduced peripheral vascular resistance, reflected by Ea, with contributions from beneficial LV remodelling and improved LV contractility. It is important to judge the effects treating HFrEF in patients with NIDCM by using indices such as Ea/Ees (sb), PRSW and TCP that reflect V–A coupling. The parameter, TCP, best expressed both the improvement in LV pump performance and the reduction in arterial load. Future studies of the treatment of NIDCM prior to replacement fibrosis may allow similar results.

References

1. Masci PG, Schuurman R, Andrea B, Ripoli A, Ccocani M, Chiappino S, Todiere G, Srebot V, Passino C, Aquaro GD, Erdin M, Lombardi M. Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging 2013; 6: 790–799.
2. Faxon DP, Halperin JL, Creager MA, Gavras H, Schick EC, Ryan TJ. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J 1981; 101: 548–556.
3. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaipe RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blockling agents. N Engl J Med 2002; 346: 1357–1365.
4. Maurer MS, Sackner-Bernstein JD, El-Khoury Rumbarger L, Yushak M, King DL, Burkhoff D. Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure. Circ Heart Fail 2009; 2: 189–196.
5. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hanson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. The relevance of tissue angiotensin-converting enzyme manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88: 11–20.
6. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992; 86: 431–438.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709–717.
8. Lieb W, Larson MG, Benjamin EJ, Yin X, Tofiger GH, Selhub J, Jacques PF, Wang TJ, Vita JA, Levy D, Vasan RS, Mitchell GF. Multimarker approach to evaluate correlates of vascular stiffness: the

Clinical trials registration

https://register.clinicaltrials.gov/Clinical Trials. Gov ID NCT00574119.

Acknowledgements

The authors thank Adam Stein, AS, RT; Francesca Sabo, BS, RT; Donald CiFelli, BS, RT; Janine E. Belote, Sr CNMT, RT (CT); Joseph Forrester, Sr CNMT, RT (CT); Barbara Konz, RN; Amber Brock, RN; Debra Rassel, RN; Linda Howerton, RN; and Brenda White, RN for their contributions to this study.

Conflict of interest

None declared.

Funding

This work was supported in part by a Discovery Grant from the Vanderbilt University Medical Center grant UL1RR024975 NCCR/NIH award UL1TR000445) from the National Center for Advancing Translational Sciences; (U01HL100398) (Dr Sawyer); Astellas Pharmaceuticals (grant REGA-14E03); National Institutes Health (grant K23 HL128928) (Dr Gupta); (T32 HL 07411-31); National of Health/National of Child Health and Human Development (K12 HD 043483-11); National Institute on Aging (Paul B. Beeson K23AG048347 award), and Eisenstein Women’s Heart Fund (Dr Bell).
18. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 1983; 245: H773–H780.

19. Kronenberg MW, Uetrecht JP, Dupont WD, Davis MH, Phelan BK, Friesinger GC. Intrinsic left ventricular contractility in normal subjects. Am J Cardiol 1988; 61: 621–625.

20. Chen CH, Feteci B, Nevo E, Rochitte CE, Chiou KR, Ding PA, Kawaguchi M, Kass DA. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol 2001; 38: 2028–2034.

21. Glower DD, Spratt JA, Snow ND, Kabas JS, Davis JW, Olsen CO, Tyson GS, Sabiston DC Jr, Rankin JS. Linearity of the Frank–Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation 1985; 71: 994–1009.

22. Lee WS, Huang WP, Yu WC, Chiou KR, Ding PY, Chen CH. Estimation of preload recruitable stroke work relationship by a single-beat technique in humans. Am J Physiol Heart Circ Physiol 2003; 284: H744–H750.

23. Bell SP, Adiksson DW, Lawson MA, Wang L, Ooi H, Sawyer DB, Kronenberg MW. Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy. J Am Heart Assoc 2014; 3: pii: e000883.

24. Bradham WS, Bell SP, Adiksson DW, Smith HM, Harrell FE Jr, Lawson MA, Ooi H, Sawyer DB, Kronenberg MW. Myocardial T1 measurement predicts beneficial LV remodeling after long-term heart failure therapy. J Card Fail 2017; 23: 262–265.

25. Cranney GB, Lotan CS, Dean L, Baxley W, Bouchard A, Pohost GM. Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography. Circulation 1990; 82: 154–163.

26. Allison JD, Flickinger FW, Wright JC, Falls DG 3rd, Prisant LM, VonDohlen TW, Frank MJ. Measurement of left ventricular mass in hypertrophic cardiomyopathy using MRI: comparison with echocardiography. Magn Reson Imaging 1993; 11: 329–334.

27. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39.

28. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, Kass DA. Effective arterial elastance as index of arterial vascular load in humans. Circulation 1992; 86: 513–521.

29. van der Velde ET, Burkhoff D, Steenjijk P, Karsdon J, Sagawa K, Baan J. Nonlinearity and load sensitivity of end-systolic pressure–volume relation of canine left ventricle in vivo. Circulation 1991; 83: 315–327.

30. Takaoka H, Suga H, Goto Y, Hata K, Takeuchi M. Cardiodynamic conditions for the linearity of preload recruitable stroke work. Heart Vessels 1995; 10: 57–68.

31. McClain LC, Wright LD, Bose RK, Spratt JA, Maier GW. Afterload sensitivity of nonlinear end-systolic pressure–volume relation vs preload recruitable stroke work in conscious dogs. J Surg Res 1998; 75: 6–17.

32. Asano H, Sasaya S, Kameyama T. Ventricular–arterial coupling in normal and failing heart in humans. Circ Res 1989; 65: 482–493.

33. Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 2006; 12: 240–245.

34. Bausers J, Heck M, Fracarollo D, Hildekann SK, Ertl G, Wehling M, Christ M. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39: 351–358.

35. Guilha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 1974; 291: 587–592.

36. Burkhoff D, Sagawa K. Ventricular efficiency predicted by an analytical model. Am J Physiol 1986; 250: R1021–R1027.

37. Sunagawa K, Maughan WL, Sagawa K. Optimal arterial resistance for the maximal stroke work studied in isolated canine left ventricle. Circ Res 1985; 56: 586–595.

38. Dekleva M, Lazic JS, Soldatovic I, Inkrot S, Arandjelovic A, Waagstein F, Gelbrich G, Cvijanovic D, Dungen HD. Improvement of ventricular–arterial coupling in elderly patients with heart failure after beta blocker therapy: results from the CIBIS-ELD Trial. Cardiovasc Drugs Ther 2015; 29: 287–294.

39. Suga H, Kitanakata K, Sakuma K. End-systolic pressure determines stroke volume from fixed end-diastolic volume in the isolated canine left ventricle under a constant contractile state. Circ Res 1979; 44: 238–249.

40. Hunter WC. End-systolic pressure as a balance between opposing effects of ejection. Circ Res 1979; 45: 139–141.

41. Igarashi Y, Goto Y, Yamada O, Ishii T, Suga H. Transient vs. steady end-systolic pressure–volume relation in dog left ventricle. Am J Physiol 1987; 252: H998–H1004.
42. Vaartjes SR, Boom HB. Left ventricular internal resistance and unloaded ejection flow assessed from pressure-flow relations: a flow-clamp study on isolated rabbit hearts. *Circ Res* 1987; 60: 727–737.

43. Baan J, Van der Velde ET. Sensitivity of left ventricular end-systolic pressure–volume relation to type of loading intervention in dogs. *Circ Res* 1988; 62: 1247–1258.

44. Shishido T, Hayashi K, Shigemi K, Sato T, Sugimachi M, Sunagawa K. Single-beat estimation of end-systolic elastance using bilinearly approximated time-varying elastance curve. *Circulation* 2000; 102: 1983–1989.

45. Bradham WS, Bell SP, Huang S, Harrell FE Jr, Adkisson DW, Lawson MA, Sawyer DB, Ooi H, Kronenberg MW. Timing of left ventricular remodeling in nonischemic dilated cardiomyopathy. *Am J Med Sci* 2018; 356: 262–267.

46. Weissler AM, Harris WS, Schoenfeld CD. Systolic time intervals in heart failure in man. *Circulation* 1968; 37: 149–159.

47. Chirinos JA, Sweitzer N. Ventricular–arterial coupling in chronic heart failure. *Card Fail Rev* 2017; 3: 12–18.

48. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. *Am J Cardiol* 2002; 90: 29–34.